» Articles » PMID: 28153104

Outcomes of Intensive Blood Pressure Lowering in Older Hypertensive Patients

Overview
Date 2017 Feb 4
PMID 28153104
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The 2014 Eighth Joint National Committee panel recommended a therapeutic target of systolic blood pressure (BP) <150 mm Hg in patients ≥60 years of age, a departure from prior recommendation of <140 mm Hg.

Objectives: This study assessed the efficacy and safety of intensive BP-lowering strategies in older (age ≥65 years) hypertensive patients.

Methods: The MEDLINE, Scopus, EMBASE, and Cochrane databases were searched for all relevant randomized controlled trials from 1965 through July 1, 2016. Cardiovascular (major adverse cardiovascular events [MACE], cardiovascular mortality, stroke, myocardial infarction, and heart failure), and safety (serious adverse events and renal failure) were evaluated. Random and fixed effects analysis were used to calculate pooled relative risks (RRs) and 95% confidence intervals (CIs).

Results: We identified 4 high-quality trials involving 10,857 older hypertensive patients with a mean follow-up of 3.1 years. Intensive BP lowering was associated with a 29% reduction in MACE (RR: 0.71; 95% CI: 0.60 to 0.84), 33% in cardiovascular mortality (RR: 0.67; 95% CI: 0.45 to 0.98), and 37% in heart failure (RR: 0.63; 95% CI: 0.43 to 0.99) compared with standard BP lowering. Rates of myocardial infarction and stroke did not differ between the 2 groups. There was no significant difference in the incidence of serious adverse events (RR: 1.02; 95% CI: 0.94 to 1.09) or renal failure (RR: 1.81; 95% CI: 0.86 to 3.80) between the 2 groups. The fixed effects model yielded largely similar results, except for an increase in the risk of renal failure (RR: 2.03; 95% CI: 1.30 to 3.18) with intensive BP-lowering therapy.

Conclusions: In older hypertensive patients, intensive BP control (systolic BP <140 mm Hg) decreased MACE, including cardiovascular mortality and heart failure. Data on adverse events were limited, but suggested an increased risk of renal failure. When considering intensive BP control, clinicians should carefully weigh benefits against potential risks.

Citing Articles

Drug-gene interactions in older patients with coronary artery disease.

Zhang S, Lv C, Dong L, Wu Y, Yin T BMC Geriatr. 2024; 24(1):881.

PMID: 39462319 PMC: 11515805. DOI: 10.1186/s12877-024-05471-7.


Optimal Systolic Blood Pressure for the Prevention of All-Cause and Cardiovascular Disease Mortality in Older Adults With Hypertension: Nationwide Population-Based Cohort Study.

Lee J, Lee K JMIR Public Health Surveill. 2024; 10:e52182.

PMID: 38861307 PMC: 11200037. DOI: 10.2196/52182.


Long Noncoding RNA MALAT1: Salt-Sensitive Hypertension.

Khan M, Kirabo A Int J Mol Sci. 2024; 25(10).

PMID: 38791545 PMC: 11122212. DOI: 10.3390/ijms25105507.


Generalisability and potential deaths averted from intensive blood pressure treatment among the elderly population in the US and China: A nationally representative cross-sectional study.

Li C, Yang C, Shao F, Liang X, Chen K, Yang T J Glob Health. 2023; 13:04100.

PMID: 37681671 PMC: 10486303. DOI: 10.7189/jogh.13.04100.


Genetic Deletion of the Homolog in Mouse Aggravates Angiotensin II-Induced Hypertension.

Tang X, Lai C, Malhi N, Chadha R, Luo Y, Liu X Noncoding RNA. 2023; 9(3).

PMID: 37218991 PMC: 10204496. DOI: 10.3390/ncrna9030031.